# Atrial Fibrillation Progression Trial

Study · id `cardio:ct-nct01570361` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01570361](<https://clinicaltrials.gov/study/NCT01570361>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01570361

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 255 participants.

## Technical summary

Registry record NCT01570361. Randomized; no masking; primary purpose treatment. Start 2012-02-13 (actual); primary completion 2018-12-19 (actual). Results posted on 2020-05-14.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 255 participants (enrolled count; ClinicalTrials.gov record NCT01570361, source copy `cardio:ctgov-nct01570361-2025-02-04`, retrieved 2026-10-26)
- Started: 2012-02-13 (actual) (ClinicalTrials.gov record NCT01570361, source copy `cardio:ctgov-nct01570361-2025-02-04`, retrieved 2026-10-26)
- Primary completion: 2018-12-19 (actual) (ClinicalTrials.gov record NCT01570361, source copy `cardio:ctgov-nct01570361-2025-02-04`, retrieved 2026-10-26)
- Completion: 2018-12-19 (actual) (ClinicalTrials.gov record NCT01570361, source copy `cardio:ctgov-nct01570361-2025-02-04`, retrieved 2026-10-26)
- Results first posted: 2020-05-14 (ClinicalTrials.gov record NCT01570361, source copy `cardio:ctgov-nct01570361-2025-02-04`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01570361-2025-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atrial Fibrillation Progression Trial
- Acronym: ATTEST
- Condition: Atrial Fibrillation
- Intervention (Device): Catheter Ablation
- Intervention (Drug): Drug Treatment
- Lead sponsor: Biosense Webster, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: 871683b78dfad9b78725233c06607e54fe0c604d7f4362fc554cf24c35e98ed6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
